Until recently, pharmaceuticals has been an incredibly arrogant industry that has never outsourced,

said Sujay Shetty, an associate director with PricewaterhouseCoopers in Mumbai. But over the next
several years, he predicts, everything in the value chain will move to different parts of the world that
are cheaper, with India a major beneficiary. The next opportunities for India could come at the more
sophisticated end of the drug making spectrum, including research and development for the worlds
drug giants and even development of proprietary medicines.
Sujay Shetty, directorul firmei PricewaterhouseCoopers din Mumbai, a declarat c industria
farmaceutic a fost pn n prezent incredibil de arogant privind externalizarea
serviciilor. Dar acesta prezice c n urmtorii ani totul din lanul de aprovizionare se va
muta n regiunile diferite ale lumii care sunt mai ieftine, India fiind principalul beneficiar.
Oportunitile Indiei ar putea proveni dintr-o gam mult mai sofisticat de producere a
medicamentelor, incluznd cercetare i dezvoltare pentru giganii mondiali ai
medicamentelor i chiar dezvoltarea medicamentelor patentate.
We can crack the problem of patented drug discovery in India at a much lower cost than in the West,
predicted Mr. Piramal, who held onto his research and development operation, Piramal Lifesciences
Limited, when he sold the rest of his company to Abbott. At Piramals main laboratory in north Mumbai,
about 300 scientists are researching new drugs aimed at inflammation, metabolic disorders and cancer.
Mainly because of lower wages, if it costs big pharmaceutical companies $1 billion to $1.5 billion to
discover a new drug, we can do it in a tenth of the cost, Mr. Piramal predicts. G. V. Prasad, chief
executive of Dr. Reddys Laboratories, said that Indian drug makers had the ability to handle product
development on a massive scale at a low cost. Dr. Reddys original diabetes drug has completed Phase
3 clinical trials the last step before seeking Food and Drug Administration approval the farthest of
any of its peers.
Domnul Piramal a prezis c putem rezolva problema patentrii descoperirii
medicamentelor, n India la un cost mult mai mic dect n Vest i este cel care i-a
continuat cercetrile i operaiunile de dezvoltare la Piramal Lifesciences Limited dup ce
i-a vndut restul companiei la Abbott. La laboratorul principal din nordul Mumbaiului,
aproximativ 300 de oameni de tiin lucreaz la medicamente noi care vor vindeca
inflamaiile, tulburrile metabolice i cancerul. Domnul Piramal prezice c dac companiile
farmaceutice mari vor avea de pltit ntre 1 miliard i 1,5 miliard privind descoperirea unui
medicament nou, n mare parte din cauza salariilor mici, noi putem s putem s facem
asta la o zecime din cost. G. V. Prasad, directorul general al Laboratoarelor Dr. Reddy`s,
declar c productorii indieni de medicamente au capacitatea de a lucra cu dezvoltarea
medicamentelor la o scar larg, la un cost redus. Medicamentul pentru diabet de la
Laboratoarele Dr. Reddy`s a finalizat faza a treia din studiile clinice ultimul pas de
dinaintea obinerii aprobrii de la Adiministraia de Alimente i Medicamente ajungnd cel
mai departe dintre toi din domeniu.
Meanwhile, at Suns stucco and glass laboratory in Gujarat, surrounded by white, pink and yellow
bougainvillea, 650 scientists, backed by tons of expensive machinery and 10,000 animals in cages, are
at work breaking down drugs with the aim of rebuilding them in cheaper ways with fewer side effects.
Revolutionary science is not only about developing a brand-new product, said T. Rajamannar, executive
vice president of Sun Pharma Advanced Research. It also means learning how to make an existing drug
very efficiently, he said. For all the potential, though, Indias drug industry has a long way to go to
fulfill its promise. India exported about 384 billion rupees ($8.3 billion) in drugs and services for the
pharmaceutical industry in the 2008-9 fiscal year, according to government figures, up 25 percent from
the year before. Recent growth, though, has been shadowed by quality problems. The F.D.A. cited
Ranbaxy for manufacturing violations several times in recent years, and in February ordered a review of
the companys global manufacturing operations.
ntre timp, la casele de sticl i stuc i nconjurate de Bougainvilla albe, roz i galbene de la
Sun Pharma Advanced Research, 650 de oameni de tiin lucreaz la metabolizarea
medicamentelor cu scopul de a le face mai ieftine cu un numr mai sczut de efecte
secundare.T. Rajamannar, vice-preedintele de la Sun Pharma Advanced Research spune
c tiina revoluionar nu se ocup doar cu dezvoltarea unui medicament nou. A declarat
c mai trebuie tiut i cum s poi mbunti un medicament deja existent ntr-un mod
foarte eficient. Deja are un mare potenial, India are de parcurs un drum foarte lung
pentru a-i ndeplini ce i-a propus. n anul fiscal 2008-2009, India a exportat medicamente
i servicii n valoare de aproape 384 de miliarde de rupii (8,3 miliarde de dolari) pentru
industria farmaceutic, iar potrivit numerelor/datelor financiare ale guvernului, asta
nseamn cu 25% mai mult dect anul trecut. Dar creterea recent a fost umbrit de
problema calitii. Adiministraia de Alimente i Medicamente a citat compania Ranbaxy n

ultimii ani pentru mai multe nclcri privind producerea medicamentelor, iar n februarie a
ordonat revizuirea operaiunilor globale de producie a companiei.